Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.56 |
| ▸ | PRKX | P51817 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634171 | 1.00 | ROCK1 (0.57) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL7000861 | 0.89 | PRKCZ (0.56) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL3133920 | 0.89 | PRKCZ (0.56) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL4067092 | 0.89 | PRKCZ (0.56) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL3127582 | 0.87 | PRKCZ (0.54) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL3809688 | 0.84 | CHRNB2 (0.63) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL3153942 | 0.84 | CHRNB2 (0.55) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL19582779 | 0.84 | CHRNB2 (0.55) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL18689816 | 0.84 | CHRNB2 (0.55) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 | |
| SCHEMBL3158901 | 0.84 | CHRNB2 (0.55) | ROCK1ROCK2KCNH2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1795192-A2 | 1-Substituted imidazole derivatives as nos inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | disclosed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-6982259-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | disclosed |
| EP-1501504-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2003092678-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | ROCK1 579/4885ROCK2 1519/4885KCNH2 2322/4885 |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | ROCK1 394/4885ROCK2 898/4885KCNH2 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.